申请人:Eli Lilly and Company
公开号:US05545636A1
公开(公告)日:1996-08-13
The present invention discloses compounds of the general formula: ##STR1## The compounds are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
本发明公开了一般公式的化合物:##STR1## 这些化合物是高度异构酶选择性的蛋白激酶C beta-1和beta-2异构酶抑制剂。因此,本发明提供了一种选择性抑制蛋白激酶C异构酶beta-1和beta-2的方法。作为beta-1和beta-2的异构酶选择性抑制剂,这些化合物在治疗与糖尿病及其并发症相关的疾病状态以及与beta-1和beta-2异构酶升高相关的其他疾病状态方面具有治疗作用。